HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
CdDrxGga1qh0L05m